Pulse
Daily clinical commentary
What just happened in the medical-news cycle, and what it means for Australian patients. AU primary tier first. Every post closes with an explicit Yes / Maybe verdict based on the evidence available.
141 posts published.
-
AI diagnostic tools for stroke and diabetes: shaky foundations
A QUT study found 125 clinical AI models for stroke and diabetes were built on unverifiable Kaggle data — a real patient safety concern.
-
Online prescribing safety: what the MHR mandate actually means
After a Victorian woman died from an overdose linked to multiple online prescribers, the AMA backs mandatory MHR uploads — but calls it just the floor.
-
TGA finds hidden prescription drugs in sexual supplements
Multiple 'natural' enhancement products sold in Australia contain undeclared sildenafil and tadalafil — a serious risk for people on heart medicines.
-
AI scribes in your GP's room: high adoption, thin regulation
40% of GPs now use AI scribes regularly, but government documents reveal these tools sit largely outside the TGA's regulatory framework — for now.
-
71% fewer heroin callouts: Melbourne injecting room evidence is in
Nine-year Monash study confirms Melbourne's supervised injecting room cut heroin ambulance callouts 71% — the strongest Australian evidence yet.
-
$700M youth mental health plan: RACGP flags the GP gap
New Headspace Plus and Youth Specialist Care Centres risk fragmenting care by leaving GPs out — the RACGP is calling it out before the models are locked in.
-
GPs lose PBS adrenaline authority — a rural patient safety crisis
The PBAC has removed the exemption letting GPs initiate PBS-subsidised adrenaline, leaving rural patients facing $120–$190 costs or specialist waits of years.
-
Pre-eclampsia raises CKD risk up to 15-fold — new cohort study
A Danish study of 286,078 pregnancies links severe proteinuria in pre-eclampsia to a 15.5-fold higher 10-year chronic kidney disease risk.
-
TGA flags liver injury risk from ashwagandha supplements
The TGA has issued a safety alert on ashwagandha after reports of liver injury — a risk relevant to anyone using it for stress, sleep, or hormonal support.
-
Your BMI is normal — but you could still be clinically obese
Research finds 1 in 4 adults with a normal BMI still meet criteria for clinical obesity. In general practice, that gap has real consequences.
-
Eight in ten cardiac patients skip rehab — and the risk is real
Only 1 in 5 Australians who had a cardiac stent attended rehabilitation. New Monash data puts a number on a longstanding and serious gap in care.
-
That 'healthier' hard seltzer? Probably ultra-processed.
George Institute audited 534 RTD drinks: 98% were ultra-processed, nearly half carried health claims. Here is what that means for your Friday night.
-
Uterine fibroids in your 40s: reassure, refer, or treat?
New GP clinical guidance makes it official: fibroid size doesn't decide management. Symptom burden and your values do. Here's what that shift means.
-
The cardinal feature of long COVID that gets missed most often
New GP guidance names post-exertional malaise as the defining feature of long COVID — and says structured pacing, not pushing through, is the right response.
-
NSW GPs can now bulk-bill ADHD assessments — what that means for you
The NSW Government is paying GP practices $600 per patient to bulk-bill ADHD consultations. For adult women who have waited for answers, here's what to know.
-
One in five of us — what we still get wrong about addiction
Monash researchers say Australia still misreads addiction as moral failing, when evidence-based treatments exist that most people never access.
-
NSW sets a THC driving limit — trauma doctors say the science isn't there
NSW introduces a legal 50 ng/mL saliva THC threshold for medicinal cannabis users. Twenty doctors warn it normalises impaired driving.
-
Australia's asthma control is still slipping — and the data says why
A new MJA study finds urgent asthma visits rose from 29% to 38% over a decade — even as SABA overuse climbs and guidelines shift to combination therapy.
-
Bowel cancer screening and the July 2026 MBS change: what patients need to know
From 1 July 2026, colonoscopy after a positive FOBT has its own MBS item — cutting billing friction for bowel cancer screening follow-up.
-
Mild cognitive impairment: what it is, and what it doesn't have to mean
New UNSW analysis: MCI doesn't always become dementia. Up to 28% revert to normal — and 14 modifiable risk factors could cut cases by 45%.
-
H5N1 detected in Australian wild birds — what you need to know
H5N1 clade 2.3.4.4b has reached Australian wildlife for the first time. Human risk is low — but if you handle birds, know the symptoms and when to see your GP.
-
Sublocade is leaving the PBS by December — and patients need a plan now
Indivior is withdrawing Sublocade (buprenorphine depot injection) from PBS by end of 2026. Stable patients have six months to plan a transition with their GP.
-
New GP incentive for veterans' mental health care starts July 2026
$99.30 DVA Mental Health GP Incentive — co-billable with Medicare MHTP items — launched 1 July 2026, following the Royal Commission into veteran suicide.
-
Sleep apnoea in midlife raises dementia risk — Monash data
Monash's Healthy Brain Project finds OSA linked to higher dementia risk scores in 40–70 year olds — and women are the most underscreened group.
-
Australia's first GP deprescribing roadmap targets benzos and opioids
SUPPORT-Meds launches Australia's first structured deprescribing program for GPs — focused on benzos for sleep and opioids for chronic non-cancer pain.
-
Tasmania extends free MenB vaccine to all infants from 1 July
Tasmania's $4m investment covers meningococcal B for infants 6 weeks to 2 years through general practice — previously private-prescription only.
-
Capvaxive on the NIP from 1 July: what changes for your patients
Australia's new 21-valent pneumococcal vaccine Capvaxive joins the NIP from 1 July, with lower age thresholds and a simplified adult schedule.
-
Queensland's skin cancer burden: what the QSkin numbers mean
QSkin data: 71% of Queenslanders aged 40–69 accessed skin cancer services over 8.5 years — making prevention the most important GP conversation in the room.
-
NSW medicinal cannabis driving bill: what GPs need to know now
NSW's proposed medcann driving laws replace zero-tolerance THC testing with a graduated framework — what GPs and patients need to know before August.
-
Prescribing cascades spike when older patients move into aged care
A study of 167,850 Australians finds prescribing cascades jump from 16.7% to 25.1% after aged care entry — a critical gap for GP and pharmacist handover.
-
Needle-free adrenaline on the PBS from 1 July — what changes
Neffy, a nasal adrenaline spray for anaphylaxis, joins the PBS on 1 July 2026, making needle-free emergency epinephrine subsidised for the first time.
-
SafeScript cut prescription-shopping by 15% — and held the gain
A Monash University study of 810,000 Victorian patients shows real-time prescription monitoring reduced multiple-prescriber events and sustained the fall.
-
Bi+ Australians in general practice: new data, persistent gaps
A Kirby Institute survey of 2,100 bi+ Australians finds high GP engagement but major gaps in GP understanding of their specific health needs.
-
Freebirth, postpartum haemorrhage, and what the evidence shows
A Melbourne obstetrician says wellness influencer Stacey Warnecke's death from postpartum haemorrhage after an unassisted birth was preventable.
-
Most GPs are not comfortable with disability care — a fixable gap
A newsGP poll finds 60 per cent of Australian GPs are not comfortable providing disability care. The gap traces back to training and NDIS design.
-
From 1 July: all pathology and radiology reports go to My Health Record
From 1 July 2026, pathologists and radiologists must upload all reports to My Health Record by default. Here is what changes for patients.
-
Australian mental health stigma runs deep — MJA survey of 6,000 adults
MJA survey of 6,032 Australians finds persistent stigma toward people with mental health conditions, including one in five doubting their personal worth.
-
Australian asthma control is getting worse — MJA nine-year comparison
New MJA research shows asthma control in Australian adults worsened between 2012 and 2021, with urgent care visits up and reliever overuse rampant.
-
Abdominal fat is now Australia's leading killer — the AIHW data explained
New AIHW data shows abdominal obesity has nearly doubled since 1995 and is now Australia's leading risk factor for death. What the numbers mean for women at 45.
-
You haven't lost focus — you're living in an attention theft economy
Macquarie University researchers explain why concentration is harder than it used to be, and what actually works to get it back.
-
NSW makes MND a notifiable disease — what this means for GPs and patients
NSW has become the first jurisdiction globally to classify motor neurone disease as notifiable, creating a mandatory registry and reducing diagnostic delays.
-
GLP-1 medications and eating disorders: the screening gap
One in three eating disorder patients in a new JAMA Psychiatry study had used GLP-1 drugs. Australian GPs are being asked to screen before prescribing.
-
Measles 2026: NSW outbreak alert and the adults who missed a dose
NSW Health has issued a 2026 inner-Sydney outbreak alert. The overlooked risk isn't children — it's adults aged 20–49 who received only one MMR dose.
-
Psilocybin for concussion: Monash opens a $1.5m MRFF trial
Monash University opens enrolment for a $1.5m psilocybin trial targeting persistent post-concussion symptoms. Here's what the research is and isn't yet.
-
New flu vaccine trial: what the recombinant difference means this winter
Doherty Institute researchers found a recombinant flu vaccine generated nearly 3× higher antibodies — and the annual-shot fatigue finding is the real story.
-
Small-town GP economics: why the numbers don't add up
Medical Republic's new analysis shows small-town GP practices earn 61% of metro hourly revenue — and the July 2025 funding change made things worse.
-
Vegemite Kids cuts sodium by 50%. Here's what matters.
New lower-sodium Vegemite Kids is out and polarising. The individual effect is modest — the cumulative population argument is what actually counts.
-
Bird flu reaches mainland Australia — and our vaccination rate has halved
H5N1 confirmed in WA wild birds this week. Direct human risk is low, but flu vaccination coverage has dropped from 45% to 26% since 2020.
-
Bulk billing is up. So are out-of-pocket costs. Both are true.
New Cleanbill data: every electorate now has a bulk billing clinic, yet out-of-pocket costs rose in 147 of 150 electorates since November 2025.
-
A government-backed MHT decision tool is coming. Here's why it matters.
Australia's first structured shared decision-making tool for menopausal hormone therapy is in development, backed by $31m in NHMRC and partner funding.
-
Why Ozempic may curb addictions — the brain mechanism explained
Researchers have identified the lateral septum as the brain region linking GLP-1 receptor agonists to reduced alcohol and substance cravings.
-
Illegal weight-loss peptides linked to liver damage in Victorian patients
Australia's CMO issued a health alert after six Victorians were hospitalised with acute liver toxicity linked to unapproved Retatrutide peptide products.
-
Menopause linked to surge in serious mental health hospitalisations
Australian research: women aged 45–54 spent 16,150 more hospital days than men for depression, bipolar disorder, and schizophrenia.
-
Breast cancer risk tools fall short for women with family history — Cochrane
Cochrane 2026: all four major breast cancer risk models show only modest accuracy for women with family history, limiting personalised decisions.
-
What the NSW birth trauma inquiry tells GPs about women leaving maternity care
Analysis of the NSW Birth Trauma Inquiry: over 75% of submissions cite disrespect or coercive care — and why this matters for general practice.
-
Stroke is the third biggest killer of women — and now striking younger
New RACGP-endorsed AusDoc update: 40,000 strokes a year, third leading cause of death for women, and an increasing burden in younger Australians.
-
COVID boosters: 30% of Australians get side effects, most resolve in 3 days
New MJA survey of 197,476 Australians finds injection site reactions and fatigue are common but brief — key data for the booster conversation with your GP.
-
Hepatitis B elimination: Australia needs 90% diagnosed — we're at 67%
Doherty Institute data shows Australia won't hit 2030 hepatitis B targets on current trajectory — with 119,000 people needing better care engagement.
-
Golden staph: cefazolin now preferred over flucloxacillin in landmark trial
The 14-country SNAP Trial finds cefazolin gives fewer deaths and kidney injuries for golden staph bloodstream infections — guidelines are likely to follow.
-
Bowel cancer screening: only 42% completing their kit
New AIHW data shows 42% of eligible Australians completed bowel screening — and GP recommendation is the most effective lever to improve that.
-
Early childhood weight gain and earlier puberty: new data
A JAMA study using Australian cohort data finds girls with high BMI trajectories may enter puberty 1.5 years earlier — and the preschool years are key.
-
GLP-1 medications and 'food noise': what patients actually say
JAMA interviews 30 GLP-1 users: reduced food noise and variable GP support are the standout themes — with implications for clinical practice.
-
Cats and childhood asthma: a 30,000-child study challenges standard advice
Swedish study of 30,277 asthmatic children finds cat ownership doesn't worsen severity or exacerbations — challenging standard avoidance advice.
-
Fibromyalgia and obesity: why siloed treatment is failing patients
New analysis shows fibromyalgia and obesity share inflammatory pathways — treating them separately amplifies both conditions.
-
The evening egg study and perimenopause sleep
Deakin's nine-week trial found evening eggs don't meaningfully improve sleep in perimenopause — and points toward what evidence actually supports.
-
Australia's deadliest drug year on record: seven deaths a day in 2024
Drug-induced deaths hit 2,596 in 2024 — the highest on record. Opioids, benzos and stimulants; and for the first time, the 50s led overdose deaths.
-
Finerenone's kidney benefit confirmed beyond diabetes: three major trials
NEJM, JAMA and The Lancet show finerenone reduces kidney failure risk in non-diabetic CKD. 1 in 10 Australians has CKD — many women don't know it.
-
Dementia prevention works. Australia's landmark trial is going national
The Maintain Your Brain RCT showed personalised coaching improved cognition over 3 years. Now MYB+ is recruiting 5,000 Australians aged 45–79 nationally.
-
1300 MEDICINE helpline closes 30 July: what changes for patients
The pharmacist-staffed 1300 MEDICINE medication advice line closes 30 July 2026 after averaging 900 calls a month. Here is what takes its place.
-
PMD and mental health: the bidirectional link GPs need to act on
A Karolinska study in JAMA Network Open finds premenstrual disorders more than double psychiatric disorder risk — and the reverse holds equally true.
-
Bulk-billing consent rule starts 1 July: what the redesign means
Written consent required for every bulk-billed visit from 1 July. The government is urgently redesigning the rules after GPs flagged aged-care chaos.
-
Endometriosis hormone therapy and bone loss: what 37 studies show
A 2026 meta-analysis confirms all major endometriosis hormone therapies reduce bone mineral density, with losses peaking in the first six months.
-
Colonoscopy and PSA: the gap between detection and survival
A 13-year colonoscopy RCT and updated Cochrane PSA review both find strong cancer detection but no significant all-cause mortality benefit — what that means.
-
New sterilisation rules for GP clinics — what this means
RACGP guidelines now require GP practices to use washer-disinfectors instead of manual pre-cleaning before sterilising instruments, by early 2028.
-
17,000 women later: what the NSW pharmacy UTI trial showed
NSW pharmacists treated over 17,000 women for uncomplicated UTIs in a year, with 80% symptom resolution. The scope-of-practice debate is only starting.
-
Social prescribing: when the treatment is community, not chemicals
A UCL study of 19,627 people found social prescribing improves wellbeing and delivers a £9 return per £1 spent — regardless of socioeconomic background.
-
Why alcohol sends you straight to the chips: the science
University of Sydney researchers found that alcohol triggers FGF21, a liver hormone creating protein cravings — and ultra-processed snacks can't satisfy.
-
A three-tier funding plan could reshape how GPs are paid
The federal Health Department is quietly developing a three-stream Medicare model that ties GP incentive payments to bulk-billing commitments.
-
Low-dose Zoladex exits Australia's PBS in November
AstraZeneca is pulling goserelin 3.6 mg from the PBS from November 2026 — here's what people with endometriosis and breast cancer should know.
-
Coronial inquest pushes GP mental health checks in firearms licensing
A Victorian coroner found the state's firearms licensing system amounts to rubber-stamping. GP involvement in fitness assessments is now policy-in-motion.
-
NDIS eligibility tightening will hit women with chronic illness hardest
Proposed NDIS changes requiring treatment exhaustion first will disproportionately burden women with ME/CFS, fibromyalgia, and complex multimorbidity.
-
Two hours of social media a day raises teens' depression risk — MJA study
A Melbourne longitudinal study of 1,195 teenagers finds more than two hours daily social media use significantly raises depression and anxiety risk one year on.
-
AJGP June 2026: a third of long-term antidepressant users lack clear indication
The AJGP June 2026 issue scrutinises long-term antidepressant use in Australia: scant benefit beyond 12 months, documented harms, set-and-forget prescribing.
-
Australia's HRT patch shortage: what the SSSI extension means for you
TGA extended estradiol patch substitution arrangements to February 2027. Here's what the Estradot and Estraderm shortage means for women on MHT.
-
TGA makes unapproved peptides a compliance priority — what to know
The TGA formally escalated unapproved peptide products as a 2026 enforcement focus. Here's what the crackdown means for patients and GPs.
-
Australia's 2025 ACS guideline: what changes for post-heart attack care
The 2025 national ACS guideline sets a new LDL-C target of less than 1.4 mmol/L after a heart attack, with PCSK9 inhibitors now step-up therapy.
-
Gut bacteria and your brain: what the 2026 dementia research actually says
Multiple 2026 studies link gut microbiome composition to dementia risk. Here is where the science sits and what it means — and does not mean — for prevention.
-
The RACGP refreshed its type 2 diabetes handbook — what changed for GPs
The RACGP has refreshed its type 2 diabetes handbook, elevating GLP-1 receptor agonists and SGLT2 inhibitors alongside persistent PBS access challenges.
-
One in three Australian cancer deaths are preventable: what the data shows
Australian research finds tobacco, UV radiation, diet, body weight, and alcohol drive roughly a third of all cancer deaths and disability-adjusted life years.
-
Early egg introduction: AU guidelines cut infant egg allergy rates by 18%
A UQ-led study published June 2026 finds a 17.7% relative drop in egg allergy after Australia updated infant feeding guidelines to introduce egg by 6 months.
-
Australia flu 2026: triple winter threat, record deaths, and the vaccine gap
The federal government's winter vaccination campaign is now live. After 2025's deadliest flu season this century, here is what you need to know before July.
-
TGA approves tolebrutinib for progressive MS: what changes
TGA registers tolebrutinib (Cenrifki) for non-relapsing secondary progressive MS — the first oral therapy for this form of MS in Australia. PBS listing pending.
-
eTG June 2026 respiratory update: triple inhalers added to asthma algorithm
Therapeutic Guidelines June 2026 adds triple inhalers for uncontrolled asthma and clarifies how type 2 airway inflammation guides stepwise treatment selection.
-
Australia's first perimenopause campaign — what it means at your GP visit
The government's 'Could This Be Perimenopause?' campaign is Australia's first national perimenopause initiative. What it means for GP consultations in 2026.
-
Teplizumab approved: Australia can now delay type 1 diabetes onset
The TGA has approved teplizumab (Tzield) to delay stage 3 type 1 diabetes onset — first new T1D therapy in 100 years. What families and GPs need to know.
-
Bowel cancer screening: why the national June campaign matters at 45
The NBCSP expanded to age 45–74. Only 41.7% of eligible Australians complete the test. A new national campaign launched 1 June aims to close that gap.
-
Acalabrutinib on the PBS: leukaemia treatment drops from $7000 to $25
Acalabrutinib plus venetoclax is PBS-listed from 1 June 2026 for CLL and SLL, cutting costs by over 99% for an estimated 1200 Australians a year.
-
Quetiapine for insomnia: new RCT data on next-day driving impairment
A Flinders University RCT found 50 mg quetiapine improved sleep but tripled attention lapses in a driving simulator — relevant for off-label use in insomnia.
-
Australia's new movement guidelines: 7,000 steps, not 10,000
Australia's updated 24-hour movement guidelines recommend 7,000 steps daily — and extend balance training to all adults for the first time.
-
Elinzanetant: Australia's second non-hormonal option for hot flushes
Lynkuet (elinzanetant) is TGA-registered in Australia — an NK1/NK3 antagonist for women who can't use MHT, including those on breast cancer endocrine therapy.
-
Australia's measles resurgence: the post-COVID vaccination gap
181 measles cases in 2025, up from near-zero in 2021. Coverage has dropped to 80% in some areas — the gap is real and the fix is straightforward.
-
Emgality now PBS-listed for episodic migraine from June 2026
Galcanezumab (Emgality) expands on the PBS to cover 8 or more migraine days monthly — previously chronic-migraine only. Cost: $25 instead of $530.
-
eTG June 2026: new contraceptive options and guidance for women over 50
eTG's June 2026 update adds Slinda and NextStellis contraceptive pills and provides new guidance for women over 50 combining contraception with menopausal HRT.
-
TGA: Pharmatech MK-677 capsules contain an undisclosed anabolic steroid
Pharmatech MK-677 capsules contain metandienone, an undisclosed anabolic steroid — TGA June 2026 safety alert, do not take this product.
-
Australia's diphtheria outbreak declared nationally significant
221 confirmed cases, 30x the recent baseline — the CMO declared diphtheria a Communicable Disease Incident of National Significance in May 2026.
-
Heart Foundation's obesity-CVD guide: when GLP-1s make clinical sense
Australia's first obesity-CVD consensus statement formally endorses GLP-1 therapies. The nuance — access, eligibility, evidence — matters.
-
Medicare's Mental Health Check In goes self-guided: what the evidence says
Medicare Mental Health Check In now offers self-guided CBT — free, no referral. Evidence is encouraging for mild symptoms and more variable beyond that.
-
After cancer, the next risk is your heart — and it's being underdetected
CVD now outranks cancer recurrence as the leading late cause of death in Australian cancer survivors. What that means for monitoring after treatment.
-
Blood pressure first-line just changed: PBS now covers dual therapy from day one
From 1 April 2026, fixed-dose antihypertensive combinations are PBS first-line. If your BP hasn't reached target on one drug, here's what changed.
-
Australia's first perimenopause campaign: recognition, finally — now what?
Australia's first national perimenopause campaign just launched. Here's what it gets right, what it leaves open, and what to do this week.
-
Australia's cardiac rehab problem: real reform, long way to go
A June 2026 MJA InSight+ analysis finds cardiac rehab is under-funded and under-referred — women and First Nations peoples are most shortchanged.
-
Australia's lung cancer screen turns one — and the gaps are showing
The NLCSP screened 50,000 high-risk Australians in year one. A 2026 MJA paper warns the program risks failing without urgent investment and equity fixes.
-
Australia's women's health PBS package: one year on, what changed
Australia's $573M women's health PBS package has reached 600,000+ women — from MHT to contraception to endometriosis treatment. Here's what it means.
-
RACGP wants one door for cannabis prescribing — but who guards it?
RACGP calls Australia's medicinal cannabis prescribing a public health risk and demands a single-step portal — but who guards the simplified door?
-
A five-minute screen that could halve the endometriosis diagnosis wait
Six-question SAFE score, built from ALSWH data on 9,000 women, could cut the six-to-eight-year endometriosis diagnostic delay in Australian general practice.
-
A national health research strategy at last — and a $300M gender gap to close
Australia's first national health research strategy commits $500M and names gender equity — arriving against a documented $300M NHMRC funding gap.
-
Brain scans find an 8% choline drop across anxiety disorders
A 2026 Molecular Psychiatry meta-analysis found lower brain choline across all anxiety subtypes. An Australian trial of 420 is underway. What this means now.
-
The Lancet has now defined menopause brain fog — here's what that changes
A Monash-led Lancet paper defines menopause brain fog: real and debilitating even when objective tests are normal. What the definition changes.
-
TGA sets clearer rules on compounded medicines — what patients need to know
New TGA guidance from May 2026 clarifies when compounded medicines are lawful, with specific restrictions on GLP-1 analogues, cannabis, and IV therapies.
-
RACGP steps up to write the rules for Australia's Urgent Care Clinics
Medicare UCCs are now permanent. The RACGP has offered to write nationally consistent profession-led standards. What this means for continuity of care.
-
RSV vaccine Arexvy® is now free for Australians 75 and over
From 15 May 2026, the RSV vaccine is free under the National Immunisation Program for Australians 75-plus. What the $445m investment means this winter.
-
Victoria funds free MenB vaccine for Year 10s — and $250 is the number
Victoria's 2026–27 budget commits $9m to free meningococcal B vaccine for Year 10 students from January 2027, removing a $250-plus cost barrier.
-
GPs can now diagnose ADHD: what Victoria's reform means for women
Victoria committed $750,000 to train 150 GPs to diagnose and treat ADHD. Adult women remain the most underdiagnosed ADHD demographic in Australia.
-
RACGP launches 2026–30 plan: what 'the system must do better' means
The RACGP unveiled its Advocacy Plan 2026–30 at the Practice Owners Conference in Sydney. Here is what the five priorities mean for you.
-
Spirometry down 31%: Australia's COPD diagnostic blind spot
National spirometry testing fell 31 per cent in seven years. Six in ten Australians with COPD have never had a confirmatory breath test done.
-
Bulk billing hits 81%: what Australia's record jump means
Australia's GP bulk billing rate hit 81.4% — the biggest quarterly jump in 20 years. 97% of Australians now within 20 minutes of a bulk billing practice.
-
3 in 5 new dads never asked about their mental health
Movember's 2026 fatherhood report finds 60% of Australian new fathers were never screened for mental health in the first year after birth.
-
PCOS is now PMOS: what the rename means for your care
Polycystic ovary syndrome has been officially renamed PMOS in a global Lancet consensus led by Monash. Here is what changes — and what does not.
-
ANDEXXA delisted: Australia loses its only specific Factor Xa reversal agent
Australia's only ARTG-approved Factor Xa reversal agent has been delisted. What changes for patients on apixaban or rivaroxaban.
-
Australia's first national menopause campaign launches today
The government's $792.9m women's health package now includes a national menopause campaign running through December 2026, backed by new Medicare coverage.
-
High-THC medicinal cannabis linked to psychiatric harms: new AU data
Monash research finds Category 5 medicinal cannabis products account for over half of TGA adverse event reports, dominated by anxiety, psychosis, and paranoia.
-
Less than 1% of Australians with insomnia get the recommended treatment
CBTi is the first-line recommended treatment for insomnia — but fewer than 1% of people with insomnia in Australia currently receive it.
-
Bowel cancer rising in younger Australians — what the microbiome data shows
Bowel cancer rates are 2-3 times higher in 1990s-born Australians. Mater Research is investigating the gut microbiome and food additive link.
-
Zoladex 3.6mg leaving the PBS in November — what women on goserelin need to know
AstraZeneca is withdrawing goserelin 3.6mg from the PBS from 1 November 2026. Women with endometriosis and HR+ breast cancer need to understand the impact now.
-
Concerta shortage extended to December 2026 — what ADHD patients need to know
TGA confirms Concerta methylphenidate remains in shortage until end of 2026. Practical options for patients navigating the gap.
-
Australia's worst diphtheria outbreak — what it means for your vaccination
230+ cases in 2026 — Australia's worst-ever diphtheria outbreak. Here's what the data shows and who should check their vaccination status.
-
Medicare Urgent Care Clinics go permanent — the access win and the trade-off
$1.8 billion makes 135 bulk-billed UCCs a permanent fixture. Here's what it means for access — and why continuity of care still matters.
-
Andexanet alfa withdrawn in Australia — what patients on apixaban need to know
Andexxa (andexanet alfa) lost provisional TGA approval on 20 May 2026 — here's what patients on apixaban or rivaroxaban need to know.
-
TGA warns against importing unapproved peptides sold online for anti-ageing
BPC-157, TB-500 and other injectable peptides circulate online with anti-ageing claims but lack TGA approval or any human safety assessment.
-
Medicare urgent care clinics go permanent — what this means for your GP care
The government locked in $1.8B to make Medicare UCCs permanent. RACGP calls for profession-led standards and better handover to GPs.
-
Psilocybin and MDMA in Australian psychiatry — three years in
Three years after TGA approved psychiatrist-only prescribing of psilocybin and MDMA, what the AU rollout has actually looked like and what it means clinically.